Zoetis Inc. (ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Symbol: ZTS
Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market cap: $28.86B
52 week range: 68.77 - 148.79

Valuation

Share price: $69.69 (close of 2026-10-02)
P/E (TTM): 11.37x
Price to book: 9.17x
Price to free cash flow: 12.46x
Enterprise value: $36.42B
Book value per share: $7.60

Price performance

Period	Change
1 day	+0.85%
5 days	-1.91%
1 month	-8.51%
3 months	-6.83%
6 months	-40.91%
Year to date	-44.61%
1 year	-52.43%
3 years	-59.65%
5 years	-64.48%
10 years	+33.99%
All time	+124.73%

Members of Congress who disclosed ZTS trades

Gilbert Ray Cisneros · Markwayne Mullin · Jefferson Shreve · Lisa McClain · Robert Bresnahan · Byron Donalds · Julie Johnson · Rick Larsen

Super investors holding ZTS

Ken Griffin (Citadel) · Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Tweedy Browne (Tweedy Browne Company LLC) · Mairs & Power (Mairs & Power Inc) · Polen Capital Mgmt (Polen Capital Management LLC) · Ray Dalio (Bridgewater Associates) · George Soros (Soros Fund Mgmt)

Profitability and growth

Return on equity: 80.25%
Return on assets: 17.28%
Gross margin: 71.84%
Net margin: 28.23%
EBITDA margin: 42.98%
Revenue growth: 2.28%
Net income growth: 7.52%
Free cash flow growth: -0.65%

Cash flow and balance sheet

Free cash flow yield (TTM): 8.02%
Current ratio: 3.08x
Net debt to EBITDA: 1.89x

Latest reported year

Period end: 2025-12-31
Fiscal year: 2025
Revenue: $9.47B
Cost of revenue: $2.67B
Gross profit: $6.80B
EBITDA: $4.07B
Net income: $2.67B
Earnings per share: $6.03
Interest expense: $222.00M
Shares outstanding: 443.44M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$9.47B	$6.80B	$2.67B	$6.03
2024-12-31	$9.26B	$6.54B	$2.49B	$5.47
2023-12-31	$8.54B	$5.98B	$2.34B	$5.08
2022-12-31	$8.08B	$5.63B	$2.11B	$4.51
2021-12-31	$7.78B	$5.47B	$2.04B	$4.29
2020-12-31	$6.67B	$4.62B	$1.64B	$3.44
2019-12-31	$6.26B	$4.27B	$1.50B	$3.14
2018-12-31	$5.83B	$3.91B	$1.43B	$2.96
2017-12-31	$5.31B	$3.53B	$864.00M	$1.76
2016-12-31	$4.89B	$3.22B	$821.00M	$1.66

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity
2025-12-31	71.84%	28.23%	80.25%
2024-12-31	70.62%	26.86%	52.12%
2023-12-31	70.03%	27.43%	46.96%
2022-12-31	69.63%	26.16%	48.01%
2021-12-31	70.38%	26.20%	44.83%
2020-12-31	69.18%	24.54%	43.41%
2019-12-31	68.18%	23.96%	55.39%
2018-12-31	67.19%	24.52%	65.35%
2017-12-31	66.55%	16.28%	48.38%
2016-12-31	65.92%	16.80%	54.77%

Cash and debt by year

Period end	Cash	Debt
2025-12-31	$2.31B	$9.04B
2024-12-31	$1.99B	$5.22B
2023-12-31	$2.04B	$6.56B
2022-12-31	$3.58B	$6.55B
2021-12-31	$3.48B	$6.59B
2020-12-31	$3.60B	$6.59B
2019-12-31	$1.93B	$5.95B
2018-12-31	$1.70B	$6.44B
2017-12-31	$1.56B	$4.95B
2016-12-31	$727.00M	$4.47B

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	$2.28B	$83.00M
2024-12-31	$2.30B	$74.00M
2023-12-31	$1.62B	$60.00M
2022-12-31	$1.33B	$62.00M
2021-12-31	$1.74B	$58.00M
2020-12-31	$1.67B	$59.00M
2019-12-31	$1.33B	$67.00M
2018-12-31	$1.45B	$53.00M
2017-12-31	$1.12B	$44.00M
2016-12-31	$497.00M	$37.00M

Dividend history

Most recent payment: 2026-07-20
Paid in the last twelve months: $2.09

Payment date	Dividend per share
2026-07-20	$0.53
2026-04-20	$0.53
2026-01-20	$0.53
2025-10-31	$0.50
2025-07-18	$0.50
2025-04-21	$0.50
2025-01-21	$0.50
2024-10-31	$0.43

Investor relations

Next earnings report

Next confirmed report: 2026-11-05
Consensus EPS estimate: $1.52

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-08-06	Jun/2026	$1.84
2026-05-07	Mar/2026	$1.61
2026-02-12	Dec/2025	$1.40
2025-11-04	Sep/2025	$1.62
2025-08-05	Jun/2025	$1.62
2025-05-06	Mar/2025	$1.40
2025-02-13	Dec/2024	$1.37
2024-11-04	Sep/2024	$1.46

Filings and sources

Company website: zoetis.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Viatris Inc (VTRS) · Teva Pharmaceutical Industries Ltd (TEVA) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Novo Nordisk A S (NVO) · GSK plc (GSK) · Veeva Systems Inc (VEEV) · Organon & Co. (OGN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades